Clinical Trials
75 trialsNEXUS-01
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Amgen
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Genentech, Inc.
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Roswell Park Cancer Institute
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Amgen
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
BActinium-1
Aktis Oncology, Inc.
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
M.D. Anderson Cancer Center
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Janssen Research & Development, LLC
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Janssen Research & Development, LLC
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Senhwa Biosciences, Inc.
A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer
Novartis
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Janux Therapeutics
AMX-500
Vir Biotechnology, Inc.
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Acerand Therapeutics Limited
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Conjupro Biotherapeutics, Inc.
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
LUTACT
University of California, San Francisco
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
STRIKE-001
K36 Therapeutics, Inc.
177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
PHAROS
TechnoGenesys, Inc.
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
University of Wisconsin, Madison
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
ASCERTAIN
AstraZeneca
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
SURGE Therapeutics
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Astellas Pharma Inc
GUARDIAN-101
Clasp Therapeutics, Inc.
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex, Inc.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Astellas Pharma Inc
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Two Fraction Prostate SBRT With DIL SIB
NYU Langone Health
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Oscotec Inc.